Skip to content

Study · Case report or series · n = 1 · 2020

3 results

Semaglutide in Cystic Fibrosis-Related Diabetes.

Gnanapragasam H, Mustafa N, Bierbrauer M, Andrea Providence T, Dandona P

The Journal of clinical endocrinology and metabolism1 Jul 2020Cited by 20 (Europe PMC)

PMID32232400 (opens in a new tab)DOI10.1210/clinem/dgaa167 (opens in a new tab)PepBankPUB-32232400
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In one patient with cystic fibrosis-related diabetes, HbA1c fell from 9.1% to 6.7% within 3 months of starting semaglutide with basal insulin.

    In plain wordsIn one patient with cystic fibrosis-related diabetes, HbA1c fell within 3 months of starting weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c in cystic fibrosis-related diabetes
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    low dose, once weekly · 3 monthsAs given in this study (human).

    Measurements

    HbA1c before
    9.1%
    baseline
    HbA1c after
    6.7%
    within 3 months

    Source sentences

    Summary
    There was a significant improvement in glycemic control, reduction in HbA1c from 9.1% to 6.7% and stable euglycemic pattern on CGM (mean glucose, 142 mg/dL; SD, 51) within 3 months of starting treatment.
    2 context sentences
    Summary · context
    The objective of this report is to demonstrate the effect of the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), to basal insulin to control glycemia in one such patient.
    Summary · context
    The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin.
  2. 02HumanCase report or seriesEfficacy outcome

    In one patient with cystic fibrosis-related diabetes, continuous glucose monitoring showed a stable euglycemic pattern within 3 months of starting semaglutide.

    In plain wordsIn one patient with cystic fibrosis-related diabetes, glucose readings stayed stable and in the normal range on weekly semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeContinuous glucose monitoring pattern
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    low dose, once weekly · 3 monthsAs given in this study (human).

    Measurements

    Mean glucose
    142 mg/dL
    CGM

    Source sentences

    Summary
    There was a significant improvement in glycemic control, reduction in HbA1c from 9.1% to 6.7% and stable euglycemic pattern on CGM (mean glucose, 142 mg/dL; SD, 51) within 3 months of starting treatment.
    2 context sentences
    Summary · context
    The objective of this report is to demonstrate the effect of the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), to basal insulin to control glycemia in one such patient.
    Summary · context
    The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin.
  3. 03HumanCase report or seriesSafety outcome

    In one patient with cystic fibrosis-related diabetes, plasma pancreatic enzyme concentrations did not increase on semaglutide.

    In plain wordsIn one patient with cystic fibrosis-related diabetes, pancreatic enzymes in the blood did not rise on semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changePlasma pancreatic enzyme concentrations
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    low dose, once weekly · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    There was no increase in plasma pancreatic enzyme concentrations.
    2 context sentences
    Summary · context
    The objective of this report is to demonstrate the effect of the addition of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), to basal insulin to control glycemia in one such patient.
    Summary · context
    The replacement of rapidly acting prandial insulin with semaglutide weekly with continuation of basal insulin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.